Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 5939

Next Previous
Drug Profile

JNJ 5939

Alternative Names: JNJ 5939; NM 26 2198; NM-26

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Numab
  • Developer Johnson & Johnson; Kaken Pharmaceutical; Numab
  • Class Anti-inflammatories; Antibodies; Bispecific antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 31 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • No development reported Inflammation

Most Recent Events

  • 28 Apr 2025 Phase-II clinical trials in Atopic dermatitis (Parenteral), prior to April 2025 (Janssen Research & Development pipeline, April 2025)
  • 20 Nov 2024 Numab Therapeutics terminates a phase I clinical trials in Atopic dermatitis in USA, Canada, Germany and Poland due to asset acquisition by Johnson & Johnson, minimum study objectives necessary to inform safety, tolerability, and dose selection for Phase 2 dose-ranging evaluation of NM26-2198 were achieved, with full completion of all healthy volunteer cohorts (SC) (NCT05859724)
  • 28 Sep 2024 No recent reports of development identified for preclinical development in Inflammation in Switzerland (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top